论文部分内容阅读
目的探讨艾塞那肽对2型糖尿病(T2DM)患者的血糖、体质量、胰岛功能等的影响。方法将50例T2DM患者分为两组,分别应用艾塞那肽(27例)和传统方案(23例)治疗,在用药3个月后,观察空腹和餐后血糖、糖化血红蛋白(HbA1c)、低血糖发生率、体质量变化、血糖波动及胰岛功能情况。结果与对照组相比,艾塞那肽组的空腹和餐后血糖、HbA1c、体质量均明显下降(均P<0.05),低血糖发生率低。结论艾塞那肽可明显改善T2DM患者的血糖及胰岛功能,降低HBA1c,使血糖达标,同时还可持续降低体质量,尤其对于初诊肥胖患者疗效显著。
Objective To investigate the effect of exenatide on blood glucose, body mass and islet function in patients with type 2 diabetes mellitus (T2DM). Methods Fifty patients with T2DM were divided into two groups and treated with exenatide (27 cases) and conventional therapy (23 cases) respectively. After 3 months of treatment, the fasting and postprandial blood glucose, HbA1c, The incidence of hypoglycemia, body mass changes, blood glucose fluctuations and pancreatic islet function. Results Compared with the control group, the fasting and postprandial blood glucose, HbA1c and body weight of the exenatide group were significantly decreased (all P <0.05), and the incidence of hypoglycemia was low. Conclusion Exenatide can significantly improve blood glucose and pancreatic islet function in patients with T2DM, reduce HBA1c, blood glucose compliance, but also continue to reduce body mass, especially for newly diagnosed obese patients with significant effect.